ArticleJournal of nanobiotechnology2026
Mitochondrial protein-enriched artificial nanovesicles: mitochondrial recovery and antioxidation for diabetic wound treatment.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Oxidative stress and mitochondrial dysfunction are major barriers to the healing of diabetic wounds (DW). Eliminating reactive oxygen species (ROS) and restoring mitochondrial function are considered effective strategies to accelerate DW healing. Although extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) have shown therapeutic potential, the quality and yield of mitochondrial components in naturally secreted EVs are limited. Thus, we employed a top-down approach, using the self-assembly properties of membrane components to develop artificial nanovesicles enriched with mitochondria-associated proteins derived from human umbilical cord MSCs. These cell-derived nanovesicles (CNVs) selectively encapsulate mitochondrial proteins, effectively reducing intracellular ROS levels and specifically restoring mitochondrial membrane potential (∆Ψm) and morphology. Furthermore, the CNVs demonstrate remarkable antioxidant and mitochondrial functional restoration capacity, involving the restoration of mitochondrial complexes I, Ⅲ, V and the uncoupling process, as well as multiple mitochondrial function-associated pathways, such as the ALDH2/HADHA/HADHB axis, the IDH2/GSR/GSH axis, and the Ca
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.